Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
GlobalData on MSN1mon
Roche’s VENTANA CLDN18 assay gains CE markRoche has gained the Conformité Européenne (CE) mark of approval for its VENTANA CLDN18 (43-14A) RxDx assay to identify ...
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Roche announced that the VENTANA CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for determining CLDN18 protein expression in ...
GlobalData on MSN28d
FDA approves Astellas’ VYLOY for gastric cancer treatmentThis is the first US approval for VYLOY, a therapy targeting claudin (CLDN)-18.2-positive tumours identified through an ...
The diagnostic, called the Ventana CLDN18 (43-14A) RxDx Assay, can help determine the status of Claudin 18 protein expression in tumors of cancer patients, helping inform clinicians about the ...
In clinical trials, CLDN18.2 positivity was determined by immunohistochemistry on gastric or GEJ tumor tissue specimens with the Ventana CLDN18 (43-14A) RxDx Assay. The Food and Drug ...
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback